NCT00811889View on ClinicalTrials.gov

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

December 31, 2010

Conditions
Chronic Kidney DiseaseType 2 DiabetesDiabetic Nephropathy
Interventions
OTHER

Placebo

Placebo

DRUG

Bardoxolone Methyl (RTA 402)

Oral, Once Daily

Trial Locations (42)

11355

Flushing

11413

Springfield Gardens

15224

Pittsburgh

15240

Pittsburgh

18103

Allentown

20036

Washington D.C.

21237

Baltimore

24153

Salem

27103

Winston-Salem

28557

Morehead City

30060

Marietta

33028

Pembroke Pines

33173

Miami

33401

West Palm Beach

33511

Brandon

33952

Port Charlotte

35294

Birmingham

36106

Montgomery

37205

Nashville

48504

Flint

55430

Brooklyn Center

60616

Chicago

61603

Peoria

70809

Baton Rouge

75390

Dallas

76104

Fort Worth

78205

San Antonio

78215

San Antonio

78229

San Antonio

78404

Corpus Christi

79935

El Paso

91773

San Dimas

91910

Chula Vista

91942

La Mesa

92505

Riverside

92691

Mission Viejo

92868

Orange

97471

Roseburg

98003

Federal Way

06762

Middlebury

04102

Portland

02904

Providence

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY